{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03822858",
      "OrgStudyIdInfo": {
        "OrgStudyId": "TISCHMS-MSCNP-003"
      },
      "Organization": {
        "OrgFullName": "Tisch Multiple Sclerosis Research Center of New York",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis",
      "OfficialTitle": "Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2021",
      "OverallStatus": "Available",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StudyFirstSubmitDate": "January 24, 2019",
      "StudyFirstSubmitQCDate": "January 29, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "January 30, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "October 5, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 13, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Tisch Multiple Sclerosis Research Center of New York",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {},
    "DescriptionModule": {
      "BriefSummary": "To give expanded access to intrathecal autologous MSC-NP treatment to patients with progressive MS who do not meet the inclusion/exclusion criteria of our Phase II stem cell trial."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Multiple Sclerosis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Mesenchymal Stem Cells",
          "Neural Progenitors",
          "Autologous",
          "Bone Marrow",
          "Multiple Sclerosis"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Expanded Access",
      "ExpandedAccessTypes": {
        "ExpAccTypeTreatment": "Yes"
      }
    },
    "ArmsInterventionsModule": {
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Intrathecal MSC-NP injection",
            "InterventionDescription": "Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.\n\n10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart."
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nDiagnosis of MS as defined by the McDonald criteria\nDiagnosis of primary progressive or secondary progressive MS\nPatients will be 18 years or older\nSignificant disability shown by an Expanded Disability Status Score (EDSS, [5]) â‰¥4.5 that was not acquired within the last 12 months *(Patients with moderate to severe cerebellar dysfunction who have an EDSS of <6.5 who are not eligible for our Ph II Version Date: 11/21/18 Version #4 9 study will be included. This is because EDSS scores are heavily related to muscle strength and not balance or coordination and most accurately reflect paraparesis. Also there are patients with MS who have disabling upper limb coordination dysfunction but EDSS scores of better than 6.5 who are not suitable for the Phase II study but may benefit from this therapy).\nStable disease state as evidenced by a lack of gadolinium-enhancing lesions on an MRI and by a stable MRI disease burden (number of T2 lesions and size of lesions) in the last six months and no significant change in EDSS (1 point or more) in the last 12 months\nDoes not qualify for the inclusion/exclusion criteria of our Phase II stem cell trial. For example, patients with EDSS >6.5 or MS symptom onset and/or duration of disease >15 years\n\nExclusion Criteria:\n\nAll patients who have had any prior stem cell treatments, including HSCT\nPregnant or nursing mothers or any woman intending to become pregnant in the next three years\nUse of systemic chemotherapeutic or anti-mitotic medications within three months of study start date due to the possibility of interference with bone marrow procedure\nHistory of central nervous system infection or immunodeficiency syndromes due to increased risk of CNS infection\nPatients who are anticipated to have difficultly accessing the intrathecal space related to scoliosis, obesity, or any other relevant factors determined by the PI.\nPatients who have not tried available therapies for their progressive MS",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Saud A Sadiq, MD, FAAN",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "212 265 8070",
            "CentralContactEMail": "ssadiq@tischms.org"
          },
          {
            "CentralContactName": "Violaine Harris, PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "212 265 8070",
            "CentralContactEMail": "vharris@tischms.org"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Saud A Sadiq, MD, FAAN",
            "OverallOfficialAffiliation": "Tisch MS Research Center of New York",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Tisch MS Research Center of New York",
            "LocationStatus": "Available",
            "LocationCity": "New York",
            "LocationState": "New York",
            "LocationZip": "10019",
            "LocationCountry": "United States",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Saud Sadiq, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "212-265-8070",
                  "LocationContactEMail": "ssadiq@tischms.org"
                },
                {
                  "LocationContactName": "Saud A. Sadiq, MD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "29449193",
            "ReferenceType": "background",
            "ReferenceCitation": "Harris VK, Stark J, Vyshkina T, Blackshear L, Joo G, Stefanova V, Sara G, Sadiq SA. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis. EBioMedicine. 2018 Mar;29:23-30. doi: 10.1016/j.ebiom.2018.02.002. Epub 2018 Feb 3."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Related Info",
            "SeeAlsoLinkURL": "http://www.ebiomedicine.com/article/S2352-3964(18)30051-3/fulltext"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009103",
            "ConditionMeshTerm": "Multiple Sclerosis"
          },
          {
            "ConditionMeshId": "D000012598",
            "ConditionMeshTerm": "Sclerosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000020278",
            "ConditionAncestorTerm": "Demyelinating Autoimmune Diseases, CNS"
          },
          {
            "ConditionAncestorId": "D000020274",
            "ConditionAncestorTerm": "Autoimmune Diseases of the Nervous System"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000003711",
            "ConditionAncestorTerm": "Demyelinating Diseases"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11212",
            "ConditionBrowseLeafName": "Multiple Sclerosis",
            "ConditionBrowseLeafAsFound": "Multiple Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14567",
            "ConditionBrowseLeafName": "Sclerosis",
            "ConditionBrowseLeafAsFound": "Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21466",
            "ConditionBrowseLeafName": "Multiple Sclerosis, Chronic Progressive",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21251",
            "ConditionBrowseLeafName": "Demyelinating Autoimmune Diseases, CNS",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21247",
            "ConditionBrowseLeafName": "Autoimmune Diseases of the Nervous System",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6061",
            "ConditionBrowseLeafName": "Demyelinating Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    }
  }
}